trending Market Intelligence /marketintelligence/en/news-insights/trending/Y3pkJIncMmQ8oEm6TWRhgQ2 content esgSubNav
In This List

AstraZeneca's Farxiga approved to cut admission risk in US diabetes patients


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

AstraZeneca's Farxiga approved to cut admission risk in US diabetes patients

SNL Image

AstraZeneca PLC said the U.S. Food and Drug Administration approved Farxiga to cut the risk of hospitalization for heart failure in certain patients with type 2 diabetes.

Farxiga, or dapagliflozin, can now be used by adult patients with type 2 diabetes and established cardiovascular disease or multiple heart-related risk factors to reduce the risk of hospitalization for heart failure.

The approval is based on data from a late-stage study called Declare-Timi 58, in which Farxiga was shown to reduce the likelihood of hospitalization for heart failure or heart-related death, the Cambridge, U.K.-based drugmaker said.

Taking Farxiga cut hospitalizations for heart failure by 36% in patients with a reduced ejection fraction — a measure of how much blood the heart pumps out with each contraction. For those without reduced ejection fraction, the drop in hospitalizations was 24%.

In August, the European Commission approved a label update for Farxiga — marketed in the EU as Forxiga — expanding the medicine's marketing authorization to include positive cardiovascular outcomes. Farxiga is being evaluated by Chinese regulators, with a decision expected in the first half of 2020.

Farxiga belongs to a class of drugs known as SGLT-2 inhibitors — along with Johnson & Johnson's Invokana and Boehringer Ingelheim GmbH's Jardiance — and is approved to improve glycemic control in adults with type 2 diabetes. This class of therapies, also known as gliflozin drugs, works by absorbing glucose via the kidneys so that excess glucose is passed out of the body via urination.